Protagonist Therapeutics Inc

2026-09-02 20:08; UTC

Protagonist Therapeutics shares are lower despite Barclays setting a $180 price target following the approval of Mimrylo for polycythemia vera treatment.

2026-09-01 19:36; UTC

Protagonist Therapeutics shares are lower today, despite analysts raising price targets following the approval of Mimrylo. Barclays set a target of $180.

2026-08-28 20:02; UTC

Protagonist Therapeutics Inc is declining during Friday's session, reversing earlier gains amid rising U.S. Treasury yields and broader market dynamics.

2026-08-27 20:07; UTC

Protagonist Therapeutics Inc shares are lower during Thursday's session, continuing a decline since Wednesday amid broader market conditions and economic resilience signals.

2026-08-26 20:08; UTC

Protagonist Therapeutics Inc shares are trading higher today. No specific news was identified to explain the movement amid mixed broader market conditions.

2026-08-25 23:36; UTC

Protagonist Therapeutics Inc. sees modest gains in after-market trading amid a broader market backdrop of declining crude oil prices and easing geopolitical tensions.

2026-08-24 20:06; UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

2026-08-21 20:06; UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

2026-08-20 19:31; UTC

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.

2026-08-19 19:46; UTC

Protagonist Therapeutics Inc shares are lower today, retracing from earlier highs. The price remains above its 20-day moving average amid no specific news.

2026-08-17 19:46; UTC

BMO Capital raised Protagonist Therapeutics' price target to $178, maintaining an Outperform rating, as shares trade higher amid positive pipeline developments.

2026-08-14 22:36; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

2026-08-13 20:06; UTC

Protagonist Therapeutics shares are lower amid insider selling concerns following CEO Dinesh V. Patel's recent stock transactions. The decline reflects broader sector trends.

2026-08-12 23:31; UTC

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

2026-08-11 23:01; UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

2026-08-10 23:46; UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

2026-08-06 19:52; UTC

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

2026-08-05 22:02; UTC

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

2026-08-04 21:03; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

2026-08-03 19:36; UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

2026-07-31 19:36; UTC

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

2026-07-30 21:02; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

2026-07-29 19:43; UTC

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

2026-07-28 21:01; UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

2026-07-27 20:02; UTC

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

2026-07-22 19:42; UTC

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

2026-07-21 19:06; UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

2026-07-20 19:41; UTC

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.